홈EKSO • NASDAQ
add
엑소 바이오닉스
전일 종가
$0.79
일일 변동폭
$0.72 - $0.78
52주 변동폭
$0.50 - $2.50
시가총액
1604.07만 USD
평균 거래량
187.26만
주가수익률
-
배당수익률
-
기본 거래소
NASDAQ
뉴스
재무
손익계산서
수익
순이익
(USD) | 2024년 9월info | 전년대비 변동 |
---|---|---|
수익 | 412.90만 | -10.38% |
운영비 | 484.80만 | -10.01% |
순이익 | -207.20만 | 38.42% |
순이익률 | -50.18 | 31.30% |
주당 수익 | — | — |
EBITDA | -223.20만 | 10.97% |
유효 세율 | — | — |
대차대조표
총자산
총부채
(USD) | 2024년 9월info | 전년대비 변동 |
---|---|---|
현금 및 단기 투자 | 829.20만 | -16.55% |
총자산 | 2920.90만 | -6.33% |
총부채 | 1433.90만 | -9.96% |
총자기자본 | 1487.00만 | — |
발행 주식 | 2199.84만 | — |
주가순자산비율 | 1.16 | — |
총자산이익률 | -23.48% | — |
자본이익률 | -33.02% | — |
현금 흐름
순현금흐름
(USD) | 2024년 9월info | 전년대비 변동 |
---|---|---|
순이익 | -207.20만 | 38.42% |
영업 현금 흐름 | -227.70만 | 32.09% |
투자 현금 흐름 | -8.00천 | 52.94% |
자금 조달 현금 흐름 | 469.10만 | — |
순현금흐름 | 240.70만 | 171.42% |
잉여 현금 흐름 | -111.28만 | 57.80% |
정보
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community. Wikipedia
CEO
설립
2005
웹사이트
직원 수
70